Solsys Medical, LLC

Canaccord Genuity acts as Financial Advisor to Solsys Medical, LLC on its sale to Misonix, Inc.

Canaccord Genuity is pleased to announce that on September 27, 2019, Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices, reported the closing of its acquisition of Solsys Medical, LLC, a privately-held regenerative medical company focused on advanced wound care, in an all-stock transaction valued at approximately $109 million on the date prior to closing. Following the close of the transaction, Misonix shareholders now own approximately 64% of the combined entity, and former Solsys Medical unitholders own approximately 36%.

Canaccord Genuity acted as financial advisor to Solsys Medical and its Board of Directors in connection with the transaction.

Solsys Medical markets and distributes an advanced wound care product designed to help healthcare professionals treat difficult-to-heal and chronic wounds. The company’s leading product, TheraSkin, is a clinically proven, minimally manipulated, living human split-thickness skin allograft that is cryopreserved to retain living cells and growth factors while maintaining a mature native human dermal architecture. TheraSkin’s versatility in applications and sizes reduces product waste and helps drive operational efficiencies to better manage the total cost of care and quality outcomes needed to treat chronic wounds.

Misonix designs, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration.